Cancer: A novel "no-nonsense" approach to treatment

Oncology Research

Volumn 19, Issue 2, 2010, Pages 55-66

  Loudon, John A ^a  

^a Perfect Dental   (Australia)

Author keywords

Aminoglycosides; Ataluren; Nonsense mutations; Ribosomal read through; Tumor suppressor proteins

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE DERIVATIVE;

CANCER THERAPY; CODON; CYSTIC FIBROSIS; HUMAN; MUSCULAR DYSTROPHY; NEOPLASM; NONSENSE MUTATION; PRIORITY JOURNAL; REVIEW; THALASSEMIA;

EID: 79951541972     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12864748215124     Document Type: Review

References (69)

1. Parris, G. E. Clinically significant cancer evolves from transient mutated and/or aneuploid neoplasia by cell fusion to form unstable syncytia that give rise to ecologically viable parasite species. Med. Hypotheses 65:846-850; 2005.
2. Alain, T.; Muzik, H.; Otsuka, S.; Chan, S.; Magliocco, T.; Diaz, R.; Forsyth, P. A.; Morris, D.; Bebb, G. Susceptibility of mantle cell lymphomas to reovirus oncolysis. Leuk. Res. 34:100-108; 2010.
3. Figueiredo, M. L.; Kim, Y.; St John, M. A.; Wong, D. T. p12CDK2-AP1 gene therapy strategy inhibits tumor growth in an in vivo mouse model of head and neck cancer. Clin. Cancer Res. 11:3939-3948; 2005.
4. Voorhoeve, P. M. MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? Biochim. Biophys. Acta 1805:72-86; 2010.
5. Schwartz, G. K.; Dickson, M. A.; Callahan, L. A.; Darby, C. H.; Llorente, M.; Cao, Y.; Dials, H. J.; Miller, L. L.; Miao, H. H. Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer. J. Clin. Oncol. 28:7s; 2010.
6. Granewald, F. S.; Prota, A. E.; Giese, A.; Ballmer-Hofer, K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim. Biophys. Acta 1804:567-580; 2010.
7. Salvatori, F.; Breveglieri, G.; Zuccato, C.; Finotti, A.; Bianchi, N.; Borgatti, M.; Feriotto, G.; Destro, F.; Canella, A.; Brognara, E.; Lampronti, I.; Breda, L.; Rivella, S.; Gambari, R. Production of beta-globin and adult haemoglobin following G418 treatment of erythroid precursor cells from homozygous beta(0)39 thalassemia patients. Am. J. Hematol. 84:720-728; 2009.
8. Manuvakhova, M.; Keeling, K.; Bedwell, D. M. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6:1044-1055; 2000.
9. Magnet, S.; Blanchard, J. S. Molecular insights into aminoglycoside action and resistance. Chem. Rev. 105: 477-498; 2005.
10. Hirawat, S.; Welch, E. M.; Elfring, G. L.; Northcutt, V.J.; Paushkin, S.; Hwang, S.; Leonard, E. M.; Almstead, N. G.; Ju, W.; Peltz, S. W.; Miller, L. L. Safety, tolerability and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single and multiple dose administration to healthy male and female volunteers. J. Clin. Pharmacol. 47:430-444; 2007.
11. Rowe, S. M.; Clancy, J. P. Pharmaceuticals targeting nonsense mutations in genetic diseases: Progress in development. BioDrugs 23:165-174; 2009.
12. Welch, E. M.; Barton, E. R.; Zhuo, J.; Tomizawa, Y.; Friesen, W. J.; Trifillis, P.; Paushkin, S.; Patel, M.; Trotta, C. R.; Hwang, S.; Wilde, R. G.; Karp, G.; Takasugi, J.; Chen, G.; Jones, S.; Ren, H.; Moon, Y. C.; Corson, D.; Turpoff, A. A.; Campbell, J. A.; Conn, M. M.; Khan, A.; Almstead, N. G.; Hedrick, J.; Mollin, A.; Risher, N.; Weetall, M.; Yeh, S.; Branstrom, A. A.; Colacino, J. M.; Babiak, J.; Ju, W. D.; Hirawat, S.; Northcutt, V. J.; Miller, L. L.; Spatrick, P.; He, F.; Kawana, M.; Feng, H.; Jacobson, A.; Peltz, S. W.; Sweeney, H. L. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91; 2007.
13. Becq, F. Cystic fibrosis transmembrane conductance regulator modulators for personalized drug treatment of cystic fibrosis: Progress to date. Drugs 70:241-259; 2010.
14. Keeling, K. M.; Bedwell, D. M. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J. Mol. Med. 80:367-376; 2002.
15. Edson, R. S.; Terrell, C. L. The aminoglycosides. Mayo Clin. Proc. 74:519-528; 1999.
16. Hamed, S. A. Drug evaluation: PTC-124 - a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. Drugs 9:783-789; 2006.
17. Atkinson, J.; Martin, R. Mutations to nonsense codons in human genetic disease: Implications for gene therapy by nonsense suppressor tRNAs. Nucleic Acids Res. 22:1327-1334; 1994.
18. Mort, M.; Ivanov, D.; Cooper, D. N.; Chuzhanova, N. A. A meta-analysis of nonsense mutations causing human genetic disease. Hum. Mutat. 29:1037-1047; 2008.
19. Stratton, M. R.; Campbell, P. J.; Futreal, P. A. The cancer genome. Nature 458:719-724; 2009.
20. Harbour, J. W. Overview of RB gene mutations in patients with retinoblastoma. Implications for clinical genetic screening. Ophthalmology 105:1442-1447; 1998.
21. Karam, R.; Carvalho, J.; Bruno, I.; Graziadio, C.; Senz, J.; Huntsman, D.; Carneiro, F.; Seruca, R.; Wilkinson, M. F.; Oliveira, C. The NMD mRNA surveillance pathway down regulates aberrant E-cadherin transcripts in gastric cancer cells and CDH1 mutation carriers. Oncogene 27:4255-4260; 2008.
22. Nannuru, K. C.; Singh, R. K. Tumor-stromal interactions in bone metastasis. Curr. Osteoporos. Rep. 8:105-113; 2010.
23. Guarino, M.; Rubino, B.; Ballabio, G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39:305-318; 2007.
24. Roger, L.; Jullien, L.; Gire, V.; Roux, P. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J. Cell Sci. 123:1295-1305; 2010.
25. Clark, P. E. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 76: 939-945; 2009.
26. Pantuck, A. J.; An, J.; Liu, H.; Rettig, M. B. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res. 70:752-761; 2010.
27. Friedrich, C. A. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum. Mol. Genet. 10:763-767; 2001.
28. Shikata, K.; Kukita, Y.; Matsumoto, T.; Esaki, M.; Yao, T.; Mochizuki, Y.; Hayashi, K.; Iida, M. Gastric juvenile polyposis associated with germline SMAD4 mutation. Am. J. Med. Genet. 134:326-329; 2005.
29. Rossi, M.; Ionov, Y.; Bakin, A.; Cowell, J. Truncating mutations in the ACVR2 gene attenuates activin signaling in prostate cancer cells. Cancer Genet. Cytogenet. 163: 123-129; 2005.
30. Kittles, R. A.; Baffoe-Bonnie, A. B.; Moses, T. Y.; Robbins, C. M.; Ahaghotu, C.; Huusko, P.; Pettaway, C.; Vijayakumar, S.; Bennett, J.; Hoke, G.; Mason, T.; Weinrich, S.; Trent, J. M.; Collins, F. S.; Mousses, S.; Bailey-Wilson, J.; Furbert-Harris, P.; Dunston, G.; Powell, I. J.; Carpten, J. D. A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J. Med. Genet. 43: 507-511; 2006.
31. Zisch, A. H.; Pasquale, E. B. The Eph family: A multitude of receptors that mediate cell recognition signals. Cell Tissue Res. 290:217-226; 1997.
32. Tyagi, A.; Sharma, Y.; Agarwal, C.; Agarwal, R. Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm. Res. 9:2143-2150; 2008.
33. Langemeijer, S. M.; Kuiper, R. P.; Berends, M.; Knops, R.; Aslanyan, M. G.; Massop, M.; Stevens-Linders, E.; van Hoogen, P.; van Kessel, A. G.; Raymakers, R. A.; Kamping, E. J.; Verhoef, G. E.; Verburgh, E.; Hagemeijer, A.; Vandenberghe, P.; de Witte, T.; van der Reijden, B. A.; Jansen, J. H. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41:838-842; 2009.
34. Sanada, M.; Suzuki, T.; Shih, L. Y.; Otsu, M.; Kato, M.; Yamazaki, S.; Tamura, A.; Honda, H.; Sakata-Yanagimoto, M.; Kumano, K.; Oda, H.; Yamagata, T.; Takita, J.; Gotoh, N.; Nakazaki, K.; Kawamata, N.; Onodera, M.; Nobuyoshi, M.; Hayashi, Y.; Harada, H.; Kurokawa, M.; Chiba, S.; Mori, H.; Ozawa, K.; Omine, M.; Hirai, H.; Nakauchi, H.; Koeffler, H. P.; Ogawa, S. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460:904-908; 2009.
35. Zhang, C. L.; Tada, M.; Kobayashi, H.; Nozaki, M.; Moriuchi, T.; Abe, H. Detection of PTEN nonsense mutation and psiPTEN expression in central nervous system high-grade astrocytic tumors by a yeast-based stop codon assay. Oncogene 19:4346-4353; 2000.
36. Forbes, S. A.; Tang, G.; Bindal, N.; Bamford, S.; Dawson, E.; Cole, C.; Kok, C. Y.; Jia, M.; Ewing, R.; Menzies, A.; Teague, J. W.; Stratton, M. R.; Futreal, P. A. COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res. 38:D652-657; 2010.
37. Lynch, E.; Ostermeyer, E.; Lee, M.; Arena, J.; Ji, H.; Dann, J.; Swisshelm, K.; Suchard, D.; MacLeod, P.; Kvinnsland, S. Inherited mutations in PTEN that are associated with breast cancer, Cowden disease and juvenile polyposis. Am. J. Hum. Genet. 61:1254-1260; 1997.
38. Stella, A.; Wagner, A.; Shito, K.; Lipkin, S. M.; Watson, P.; Guanti, G.; Lynch, H. T.; Fodde, R.; Liu, B. A non-sense mutation in MLH1 causes exon skipping in three unrelated HNPCC families. Cancer Res. 61:7020-7024; 2001.
39. Manzano, R. G.; Navarro, E. M.; Eugenieva, E.; Morejón, F. J. F.; Farré, J.; Brugarolas, A. A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib. Clin. Transl. Oncol. 10:442-444; 2008.
40. Perrin-Vidoz, L.; Sinilnikova, O. M.; Stoppa-Lyonnet, D.; Lenoir, G. M.; Mazoyer, S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum. Mol. Genet. 11:2805-2814; 2002.
41. Ware, M. D.; DeSilva, D.; Sinilnikova, O. M.; Stoppa-Lyonnet, D.; Tavtigian, S. V.; Mazoyer, S. Does non-sense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? Oncogene 25:323-328; 2006.
42. Laplace-Marieze, V.; Presneau, N.; Girodet, C.; Vidal, V.; Vaurs, C.; Rio, P.; Bignon, Y-J. New nonsense mutation in the breast cancer-1 gene in a French site-specific breast cancer family. Hum. Mutat. 9:474-475; 1999.
43. Patsialou, A.; Wyckoff, J.; Wang, Y.; Goswami, S.; Stanley, E. R.; Condeelis, J. S. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res. 69:9498-9506; 2009.
44. Suzuki, H.; Zhou, X.; Yin, J.; Lei, J.; Jiang, H. Y.; Suzuki, Y.; Chan, T.; Hannon, G. J.; Mergner, W. J.; Abraham, J. M.; Melzer, S. J. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers. Hum. Mol. Genet. 4:1883-1887; 1995.
45. Dekairelle, A. F.; Brichard, B.; Delhez, H.; Gala, J. L. Identification of a transcriptionally inactive p53 mutant by functional analysis of separated alleles in yeasts (FASAY) in a child osteosarcoma tumor: A case report. Pediatr. Hematol. Oncol. 21:321-328; 2004.
46. Miyaki, M.; Iijima, T.; Yasuno, M.; Kita, Y.; Hishima, T.; Kuroki, T.; Mori, T. High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas. Oncogene 21:6689-6693; 2002.
47. Toguchida, J.; Yamaguchi, T.; Ritchie, B.; Beauchamp, R. L.; Dayton, S. H.; Herrera, G. E.; Yamamuro, T.; Kotoura, Y.; Sasaki, M. S.; Little, J. B.; Weichselbaum, R. R.; Ishizaki, K.; Yandell, D. W. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 52:6194-6199; 1992.
48. Rutherford, J.; Chu, C. E.; Duddy, P. M.; Charlton, R. S.; Chumas, P.; Taylor, G. R.; Lu, X.; Barnes, D. M.; Camplejohn, R. S. Investigations on a clinically and functionally unusual and novel germline p53 mutation. Br. J. Cancer 20:1592-1596; 2002.
49. Bernardini, M. Q.; Baba, T.; Lee, P. S.; Barnett, J. C.; Sfakionos, G. P.; Alvarez Secord, A.; Murphy, S. K.; Iversen, E.; Marks, J. R.; Berchuck, A. Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer 10:237; 2010.
50. Yagi, H.; Yotsumoto, F.; Miyamoto, S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol. Cancer Ther. 7:3441-3451; 2008.
51. Frebourg, T.; Barbier, N.; Yan, Y. X.; Garber, J. E.; Dreyfus, M.; Fraumeni, Jr., J.; Li, F. P.; Friend, S. H. Germline p53 mutations in 15 families with Li-Fraumeni syndrome. Am. J. Hum. Genet. 56:608-615; 1995.
52. De Moura, J.; Kavalec, F. L.; Doghman, M.; Rosati, R.; Custodio, G.; Lalli, E.; Cavallari, G. M.; Santa Maria, J.; Figueiredo, B. C. Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage. Int. J. Oncol. 36:983-990; 2010.
53. Solomon, H.; Brosh, R.; Buganim, Y.; Rotter, V. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: Cooperative events in tumorigenesis. Discov. Med. 9:448-454; 2010.
54. Okinaka, R. T.; Perez-Castro, A. V.; Sena, A.; Laubscher, K.; Strniste, G. F.; Park, M. S.; Hernandez, R.; MacInnes, M. A.; Kraemer, K. H. Heritable genetic alterations in a xeroderma pigmentosum group G/Cockayne syndrome pedigree. Mutat. Res. 385:107-114; 1997.
55. Cleaver, J. E.; Lam, E. T.; Revet, I. Disorders of nucleotide excision repair: The genetic and molecular basis of heterogeneity. Nat. Rev. Genet. 10:756-768; 2009.
56. Oh, K. S.; Khan, S. G.; Jaspers, N. G.; Raams, A.; Ueda, T.; Lehmann, A.; Friedmann, P. S.; Emmert, S.; Gratchev, A.; Lachlan, K.; Lucassan, A.; Baker, C. C.; Kraemer, K. H. Phenotypic heterogeneity in the XPB DNA helicase gene (ERCC3): Xeroderma pigmentosum without and with Cockayne syndrome. Hum. Mutat. 27:1092-1103; 2006.
57. Wolf, M.; Edgren, H.; Muggerud, A.; Kilpinen, S.; Huusko, P.; Sørlie, T.; Mousses, S.; Kallioniemi, O. NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer. Cell Oncol. 27:169-173; 2005.
58. Huusko, P.; Ponciano-Jackson, D.; Wolf, M.; Kiefer, J. A.; Azorsa, D. O.; Tuzmen, S.; Weaver, D.; Robbins, C.; Moses, T.; Allinen, M.; Hautaniemi, S.; Chen, Y.; Elkahloun, A.; Basik, M.; Bova, G. S.; Bubendorf, L.; Lugli, A.; Sauter, G.; Schleutker, J.; Ozcelik, H.; Elowe, S.; Pawson, T.; Trent, J. M.; Carpten, J. D.; Kallioniemi, O. P.; Mousses, S. Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat. Genet. 36:979-983; 2004.
59. Song, Y. K.; Huusko, P.; Bilke, S.; Greer, B.; Wei, J. S.; Chen, Q-R.; Khan, J. Nonsense-mediated decay microarray analysis identifies potential tumor suppressor genes in neuroblastoma. Proc. Am. Assoc. Cancer Res. 47:3308; 2006.
60. Noensie, E. N.; Dietz, H. C. A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition. Nat. Biotechnol. 19:434-439; 2001.
61. Petrovic, N.; Black, T. A.; Fabian, J. R.; Kane, C.; Jones, C. A.; Loudon, J. A.; Abonia, J. P.; Sigmund, C. D.; Gross, K. W. Role of proximal promoter elements in regulation of renin gene transcription. J. Biol. Chem. 271: 22499-22505; 1996.
62. Shahani, K.; Swaminathan, S. K.; Freeman, D.; Blum, A.; Ma, L.; Panyam, J. Injectable sustained release microparticles of curcumin: A new concept for cancer chemoprevention. Cancer Res. 70:4443-4452; 2010.
63. Zimmer, C. Evolved for cancer? Sci. Am. 18:15-21; 2008.
64. Davies, W. H. What is this life if, full of care. In: Untermeyer, L., ed. Collins Albatross book of verse. London/ Glasgow: Collins; 1974:524.
65. Sanchez-Cespedes, M.; Parrella, P.; Esteller, M.; Nomoto, S.; Trink, B.; Engles, J. M.; Westra, W. H.; Herman, J. G.; Sidransky, D. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62:3659-3662; 2002.
66. Du, L.; Damoiseaux, R.; Nahas, S.; Gao, K.; Hu, H.; Pollard, J. M.; Goldstine, J.; Jung, M. E.; Henning, S. M.; Bertoni, C.; Gatti, R. A. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J. Exp. Med. 206:2285-2297; 2009.
67. Bogdanova, N.; Cybulski, C.; Bermisheva, M.; Datsyuk, I.; Yamini, P.; Hillemanns, P.; Antonenkova, N. N.; Khusnutdinova, E.; Lubinski, J.; Dãrk, T. A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer. Breast Cancer Res Treat. 118:207-211; 2009.
68. Lambert, J. M.; Gorzov, P.; Veprintsev, D. B.; Söderqvist, M.; Segerbäck, D.; Bergman, J.; Fersht, A. R.; Hainaut, P.; Wiman, K. G.; Bykov, V. J. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15:376-388; 2009.
69. Benakanakere, I.; Besch-Williford, C.; Ellersieck, M. R.; Hyder, S. M. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: A pilot study. Endocr. Relat. Cancer 16:85-98; 2009.